Regeneron Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: Election of Directors: Joseph L. Goldstein, M.D.

Regeneron Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Joseph L. Goldstein, M.D.”): 72,398,297 for, 30,904,254 against, per its Form 8-K filed June 17, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class II directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes:”
Support: 70% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 181 asset managers below reported 31,058,888 for, 8,815,478 against, 11,211 abstained, 120 not voted.

Showing the 25 largest of 181 asset managers. See all 181 in the interactive database.

Description as filed by funds: Election of Directors: Christine A. Poon

Regeneron Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Christine A. Poon”): 79,409,070 for, 24,004,880 against, per its Form 8-K filed June 17, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class II directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes:”
Support: 77% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 181 asset managers below reported 34,101,720 for, 5,772,500 against, 11,210 abstained, 120 not voted.

Showing the 25 largest of 181 asset managers. See all 181 in the interactive database.

Description as filed by funds: Election of Directors: David P. Schenkein, M.D.

Regeneron Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David P. Schenkein, M.D.”): 99,241,219 for, 4,180,107 against, per its Form 8-K filed June 17, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class II directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 181 asset managers below reported 39,607,708 for, 265,616 against, 12,106 abstained, 120 not voted.

Showing the 25 largest of 181 asset managers. See all 181 in the interactive database.

Description as filed by funds: Election of Directors: Craig B. Thompson, M.D.

Regeneron Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Craig B. Thompson, M.D.”): 81,933,651 for, 21,378,567 against, per its Form 8-K filed June 17, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class II directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes:”
Support: 79% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 181 asset managers below reported 34,150,890 for, 5,723,328 against, 11,211 abstained, 120 not voted.

Showing the 25 largest of 181 asset managers. See all 181 in the interactive database.

Description as filed by funds: Election of Directors: Huda Y. Zoghbi, M.D.

Regeneron Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Huda Y. Zoghbi, M.D.”): 100,665,234 for, 2,698,397 against, per its Form 8-K filed June 17, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class II directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes:”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 181 asset managers below reported 39,584,487 for, 289,732 against, 11,211 abstained, 120 not voted.

Showing the 25 largest of 181 asset managers. See all 181 in the interactive database.

Description as filed by funds: Proposal to approve, on an advisory basis, compensation of the Named Executive Officers.

Regeneron Pharmaceuticals, Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on Schedule ”): 96,469,374 for, 6,898,268 against — passed, per its Form 8-K filed June 17, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on Schedule 14A filed April 24, 2026 was approved based upon the following votes:”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 177 managers: 38,405,161 for, 1,468,309 against, 11,211 abstained, 120 not voted. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 916 managers: 50,327,837 for, 5,453,229 against, 7,337 abstained, 21,654 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

Regeneron Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the ”): 102,503,788 for, 6,443,958 against — passed, per its Form 8-K filed June 17, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved based upon the foll…”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 184 asset managers below reported 39,819,363 for, 100,585 against, 11,210 abstained, 120 not voted.

Showing the 25 largest of 184 asset managers. See all 184 in the interactive database.